ACM Research, Inc. (“ACM” or the “Company”) (NASDAQ:ACMR), a
leading supplier of wafer cleaning technologies for advanced
semiconductor devices, today reported financial results for its
third fiscal quarter ended September 30, 2020.
ACM’s President and Chief Executive Officer Dr. David Wang
commented, “We delivered strong third quarter results with 43%
growth in revenue and 37% growth in shipments from the third
quarter of 2019. Both revenue and shipments in are new quarterly
records for ACM. We built momentum for Tahoe with another repeat
shipment, and for ECP with two repeat shipments and one first tool
delivery in the third quarter. We have good visibility for the
remainder of 2020 and have raised our outlook accordingly.”
Dr. Wang continued, “The U.S Patent Office's decision to approve
our TEBO patent is a testament to our leadership position in
advanced damage-free megasonic cleaning for advanced 3D structures.
We delivered a second-generation TEBO tool to our lead customer in
September, with revenue recognition upon qualification and
acceptance. Our plan remains on track to price the China IPO of our
subsidiary ACM Research (Shanghai), Inc. (“ACM Shanghai”) by
year-end, subject to timely registration by the China Securities
Regulatory Commission. We remain committed to the Nasdaq listing
for our Class A common stock, and are excited to move forward with
ACM Shanghai’s STAR Market share listing as we continue on our
mission to become a major global player in the semiconductor
equipment industry.”
|
Three Months Ended September 30, |
|
GAAP |
|
Non-GAAP(1) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
|
(dollars in thousands, except per share data) |
Revenue |
$ |
47,665 |
|
|
$ |
33,427 |
|
|
$ |
47,665 |
|
|
$ |
33,427 |
|
Gross
margin |
|
42.7 |
% |
|
|
48.6 |
% |
|
|
42.8 |
% |
|
|
49.1 |
% |
Income from
operations |
$ |
7,506 |
|
|
$ |
7,030 |
|
|
$ |
10,285 |
|
|
$ |
8,587 |
|
Net income (loss) attributable
to ACM Research,
Inc. |
$ |
8,627 |
|
|
$ |
8,782 |
|
|
$ |
8,969 |
|
|
$ |
10,339 |
|
Basic
EPS |
$ |
0.47 |
|
|
$ |
0.52 |
|
|
$ |
0.49 |
|
|
$ |
0.61 |
|
Diluted
EPS |
$ |
0.40 |
|
|
$ |
0.45 |
|
|
$ |
0.42 |
|
|
$ |
0.53 |
|
|
Nine Months Ended September 30, |
|
GAAP |
|
Non-GAAP(1) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousands, except per share data) |
Revenue |
$ |
111,062 |
|
|
$ |
82,916 |
|
|
$ |
111,062 |
|
|
$ |
82,916 |
|
Gross
margin |
|
45.0 |
% |
|
|
46.1 |
% |
|
|
45.1 |
% |
|
|
46.3 |
% |
Income from
operations |
$ |
16,060 |
|
|
$ |
13,942 |
|
|
$ |
20,383 |
|
|
$ |
16,861 |
|
Net income attributable to ACM
Research, Inc. |
$ |
10,251 |
|
|
$ |
14,950 |
|
|
$ |
17,568 |
|
|
$ |
17,869 |
|
Basic
EPS |
$ |
0.57 |
|
|
$ |
0.91 |
|
|
$ |
0.97 |
|
|
$ |
1.09 |
|
Diluted
EPS |
$ |
0.48 |
|
|
$ |
0.80 |
|
|
$ |
0.83 |
|
|
$ |
0.96 |
|
(1) |
Reconciliations to U.S. generally accepted accounting principles
(“GAAP”) financial measures from non-GAAP financial measures are
presented below under “Reconciliation of GAAP to Non-GAAP Financial
Measures.” Non-GAAP financial measures exclude stock-based
compensation, with respect to net income (loss) attributable to ACM
Research, Inc. and basic and diluted EPS, also exclude non-cash
changes in fair value of financial assets and
liabilities. |
|
|
Outlook
For fiscal year 2020, the Company now expects revenue to be in
the range of $145 million to $155 million, versus the previous
guidance range of $140 million to $155 million. This view assumes,
among other factors, the COVID-19 situation remains stable in China
and does not worsen on a global basis in the coming months.
Third Quarter Operating Highlights and Recent
Announcements
- Shipments. Total
shipments in the third quarter of 2020 were $59 million, versus $43
million in the third quarter of 2019 and $45 million in the second
quarter of 2020. Total shipments include deliveries for revenue in
the quarter and deliveries of systems awaiting customer acceptance
for potential revenue in future quarters.
- Continued Traction with
Tahoe. In the third quarter of 2020, ACM delivered another
Tahoe tool to its lead customer and recognized revenue upon
shipment in the quarter. The Ultra-C Tahoe tool incorporates
innovative and patented technology to deliver high cleaning
performance, but uses 80% less sulfuric acid typically consumed by
conventional high temperature single wafer cleaning tools.
- Ultra ECP Gaining
Momentum. ACM delivered two ECP ap back-end tool repeat
shipments and one ECP 3d front-end first tool in the third quarter
of 2020. The Ultra ECP ap delivers better plating performance in
the form of a more uniform metal layer at the notch area. The Ultra
ECP 3d is ACM’s newest tool in the ECP family that offers enhanced
gap filling for high aspect ratio TSV applications, which is
critical for high-density stacking of 3D chips.
- TEBO Patent
Approved. ACM Research announced last week that the U.S.
Patent & Trademark Office recently approved U.S. Patent
Application No.15/575,793 for ACM's proprietary TEBO (timely
energized bubble oscillation) technology. In addition, ACM
delivered a 2nd -generation TEBO tool to its existing lead customer
in September 2020, with revenue recognition upon qualification and
acceptance.
- Update on ACM Shanghai
Pre-IPO activities. On September 30, 2020, ACM Shanghai's
application for an initial public offering of its shares on the
STAR Market was approved by the Listing Committee of the Shanghai
Stock Exchange Commission. The STAR Market listing of ACM
Shanghai’s shares remains subject to submission of formal
registration and to review and approval by the China Securities
Regulatory Commission. The Company’s plan remains on track to price
the transaction by year-end, pending timely approvals.
Financial Summary
Unless otherwise noted, the following figures refer to the third
quarter of 2020 and comparisons are with the third quarter of
2019.
- Revenue was $47.7
million, up 42.6%, reflecting an increase in revenue from single
wafer wet cleaning and other front-end processing equipment and an
increase in revenue from back-end wafer assembly and packaging
equipment.
- Gross margin was
42.7%, versus 48.6%. Gross margin was within the range of 40.0% to
45.0% set forth in the Company’s long-term business model. The
Company expects gross margin to vary from period to period due to a
variety of factors, such as sales volume and product mix.
- Operating expenses
were $12.8 million, an increase of 39%. Non-GAAP operating
expenses, which exclude stock-based compensation, were $10.1
million, up 29%. Non-GAAP operating expenses as a percent of
revenue decreased to 21% from 23%. Higher research and development
spending on new products, increase sales activities in North
America, and China IPO-related costs contributed to the increase
from the prior-year period.
- Operating income of
$7.5 million increased 6.8%. Operating income as a percent of
revenue was 15.7% versus 21.0%. Non-GAAP operating income,
excluding the effect of stock-based compensation, was $10.3
million, up 19.8%. Non-GAAP operating income as a percent of
revenue was 21.6% versus 25.7%.
- Change in fair value of
financial liability was a loss of $6.5 million. The
non-cash, non-operating expense reflects a change in book value of
a liability indexed to the market price of ACM’s Class A common
stock, and is excluded from non-GAAP results. The obligation, which
resulted from agreements required for ACM Shanghai’s STAR Market
IPO preparation, was terminated in July 2020 upon ACM’s issuance of
a Class A common stock warrant.
- Unrealized gain on trading
securities was $9.0 million. The gain reflects the change
in market value of ACM Shanghai’s indirect investment in STAR
Market IPO shares of Semiconductor Manufacturing International
Corporation (SMIC), which began trading in mid-July 2020. The value
was marked-to-market at quarter-end, and is excluded from non-GAAP
results.
- Net
income attributable to ACM Research,
Inc. was $8.6 million, compared to $8.8 million. Non-GAAP
net income attributable to ACM Research, Inc., excluding the effect
of stock-based compensation, non-cash changes in fair value of
financial liabilities, and unrealized gains in trading securities
was $9.0 million, compared to $10.4 million. Tax-related items
(compared to a normalized 12% tax rate) and the effects of
foreign-exchange fluctuations on operating results resulted in a
net benefit of $0.3 million, compared to a net benefit of $3.4
million in the third quarter of 2019.
- Net income per diluted
share attributable to ACM Research, Inc.
was $0.40, compared to $0.45. Non-GAAP net income per diluted share
attributable to ACM Research, Inc., excluding the effect of
stock-based compensation, non-cash changes in fair value of
financial liabilities, and unrealized gains in trading securities
was $0.42, compared to $0.53. Tax-related items (compared to a
normalized 12% tax rate) and the effects of foreign-exchange
fluctuations on operating results resulted in a net benefit of
$0.02 per share, compared to a net benefit of $0.18 in the third
quarter of 2019.
- Cash and
equivalents at quarter-end were $92.2 million, versus
$86.4 million at the end of the second quarter of 2020 and $47.3
million at the end of the third quarter of 2019.
Conference Call Details
A conference call to discuss results will be held on Friday,
November 6, 2020, at 8:00 a.m. Eastern Time (9:00 p.m. China
Time).
Please register in advance to join the conference call using the
link provided below and dial in 10 minutes before the call is
scheduled to begin. Conference call access information will be
provided upon registration.
Participant Online Registration:
http://apac.directeventreg.com/registration/event/6771328
A recording of the webcast will be available on the investor
page of the ACM website at www.acmrcsh.com for one week following
the call.
Use of Non-GAAP Financial Measures
ACM presents non-GAAP gross margin, operating expenses,
operating income, net income attributable to ACM Research, Inc.,
and basic and diluted earnings per share as supplemental measures
to GAAP financial measures regarding ACM’s operational performance.
These supplemental measures exclude the impact of stock-based
compensation, which ACM does not believe is indicative of its core
operating results. In addition, non-GAAP net income (loss)
attributable to ACM Research, Inc. and basic and diluted EPS
exclude non-cash changes in fair value of financial assets and
liabilities, which ACM also believes is not indicative of its core
operating results. A reconciliation of each non-GAAP financial
measure to the most directly comparable GAAP financial measure is
provided below under “Reconciliation of Non-GAAP to GAAP Financial
Measures.”
ACM believes these non-GAAP financial measures are useful to
investors in assessing its operating performance. ACM uses these
financial measures internally to evaluate its operating performance
and for planning and forecasting of future periods. Financial
analysts may focus on and publish both historical results and
future projections based on the non-GAAP financial measures. ACM
also believes it is in the best interests of investors for ACM to
provide this non-GAAP information.
While ACM believes these non-GAAP financial measures provide
useful supplemental information to investors, there are limitations
associated with the use of these non-GAAP financial measures. These
non-GAAP financial measures may not be reported by competitors, and
they may not be directly comparable to similarly titled measures of
other companies due to differences in calculation methodologies.
The non-GAAP financial measures are not an alternative to GAAP
information and are not meant to be considered in isolation or as a
substitute for comparable GAAP financial measures. They should be
used only as a supplement to GAAP information and should be
considered only in conjunction with ACM’s consolidated financial
statements prepared in accordance with GAAP.
Forward-Looking Statements
Certain statements contained in the second and third paragraphs
of this press release, under the heading “Outlook” above, and in
the fifth bullet under “Third Quarter Operating Highlights and
Recent Announcements” above are not historical facts and may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding the intent, belief and
current expectations with respect to: the demand for ACM’s tools,
including specifically in the fourth quarter of 2020; and ACM’s
plans for completion of the STAR Market listing of shares of ACM
Shanghai by the end of 2020. Such statements, which are
expectations only, reflect management's current views, are based on
certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the
above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors,
including, but not limited to, the following, any of which could be
exacerbated even further by the continuing COVID-19 outbreak in
China and globally: anticipated customer orders or identified
market opportunities may not grow or develop as anticipated;
customer orders already received may be postponed or canceled; ACM
may be unable to obtain the qualification and acceptance of its
delivered tools when anticipated or at all, which would delay or
preclude ACM’s recognition of revenue from the sale of those tools;
suppliers may not be able to meet ACM’s demands on a timely basis;
ACM’s technologies and tools may not gain market acceptance; ACM
may be unable to compete effectively by, among other things,
enhancing its existing tools; volatile global economic, market,
industry and other conditions could result in sharply lower demand
for products containing semiconductors and for the Company's
products and in disruption of capital and credit markets; trade
regulations, currency fluctuations, political instability and war
may materially adversely affect ACM due to its substantial non-U.S.
customer and supplier base and its substantial non-U.S.
manufacturing operations. ACM cannot guarantee any future results,
levels of activity, performance or achievements; and ACM Shanghai’s
ability to obtain remaining regulatory approval for the STAR Market
IPO and listing of its shares. ACM undertakes no obligation to
publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any
change in its expectations with regard to these forward-looking
statements or the occurrence of unanticipated events.
About ACM Research, Inc.
ACM develops, manufactures and sells semiconductor process
equipment for single-wafer or batch wet cleaning, electroplating,
stress-free polishing and thermal processes that are critical to
advanced semiconductor device manufacturing, as well as wafer-level
packaging. The Company is committed to delivering customized, high
performance, cost-effective process solutions that semiconductor
manufacturers can use in numerous manufacturing steps to improve
productivity and product yield.
© ACM Research, Inc. TEBO and the ACM Research logo are
trademarks of ACM Research, Inc. For convenience, these trademarks
appear in this press release without ™ symbols, but that practice
does not mean that ACM will not assert, to the fullest extent under
applicable law, its rights to the trademarks.
For investor and media inquiries, please
contact: |
|
|
|
|
In the United States: |
The Blueshirt Group |
|
|
Ralph Fong |
|
|
+1 (415) 489-2195 |
|
|
ralph@blueshirtgroup.com |
|
|
|
|
In China: |
The Blueshirt Group Asia |
|
|
Gary Dvorchak, CFA |
|
|
+86 (138) 1079-1480 |
|
|
gary@blueshirtgroup.com |
|
|
|
ACM RESEARCH,
INC.Condensed Consolidated Balance
Sheets
|
September 30, 2020 |
|
December 31, 2019 |
|
(Unaudited) |
|
(In thousands, except share and per share data) |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
92,203 |
|
|
$ |
58,261 |
|
Restricted cash |
|
- |
|
|
|
59,598 |
|
Trading securities |
|
23,888 |
|
|
|
- |
|
Accounts receivable, less allowance for doubtful accounts of $0 as
of September 30, 2020 and December 31, 2019 |
|
59,796 |
|
|
|
31,091 |
|
Other receivables |
|
6,177 |
|
|
|
2,603 |
|
Inventories |
|
64,182 |
|
|
|
44,796 |
|
Prepaid expenses |
|
5,531 |
|
|
|
2,047 |
|
Total current assets |
|
251,777 |
|
|
|
198,396 |
|
Property, plant and equipment, net |
|
5,974 |
|
|
|
3,619 |
|
Land use right, net |
|
9,284 |
|
|
|
- |
|
Operating lease right-of-use assets, net |
|
4,568 |
|
|
|
3,887 |
|
Intangible assets, net |
|
335 |
|
|
|
344 |
|
Deferred tax assets |
|
10,093 |
|
|
|
5,331 |
|
Long-term investments |
|
6,580 |
|
|
|
5,934 |
|
Other long-term assets |
|
8,008 |
|
|
|
192 |
|
Total assets |
|
296,619 |
|
|
|
217,703 |
|
Liabilities, Redeemable Non-controlling Interests and
Stockholders’ Equity |
|
|
|
Current liabilities: |
|
|
|
Short-term borrowings |
|
28,327 |
|
|
|
13,753 |
|
Accounts payable |
|
35,639 |
|
|
|
13,262 |
|
Advances from customers |
|
8,011 |
|
|
|
9,129 |
|
Income taxes payable |
|
3,589 |
|
|
|
3,129 |
|
Other payables and accrued expenses |
|
18,494 |
|
|
|
12,874 |
|
Current portion of operating lease liability |
|
1,388 |
|
|
|
1,355 |
|
Deferred revenue |
|
819 |
|
|
|
- |
|
Total current liabilities |
|
96,267 |
|
|
|
53,502 |
|
Long-term operating lease liability |
|
3,180 |
|
|
|
2,532 |
|
Other long-term liabilities |
|
6,454 |
|
|
|
4,186 |
|
Total liabilities |
|
105,901 |
|
|
|
60,220 |
|
Commitments and contingencies |
|
|
|
Redeemable non-controlling interests |
|
- |
|
|
|
60,162 |
|
Stockholders’ equity: |
|
|
|
Common stock – Class A, par value $0.0001: 50,000,000 shares
authorized as of September 30, 2020 and December 31, 2019;
16,657,135 shares issued and outstanding as of September 30, 2020
and 16,182,151 shares issued and outstanding as of December 31,
2019 |
|
2 |
|
|
|
2 |
|
Common stock–Class B, par value $0.0001: 2,409,738 shares
authorized as of September 30, 2020 and December 31, 2019;
1,802,606 shares issued and outstanding as of September 30, 2020
and 1,862,608 shares issued and outstanding as of December 31,
2019 |
|
- |
|
|
|
- |
|
Additional paid in capital |
|
100,145 |
|
|
|
83,487 |
|
Accumulated surplus |
|
25,758 |
|
|
|
15,507 |
|
Accumulated other comprehensive income (loss) |
|
1,037 |
|
|
|
(1,675 |
) |
Total ACM Research, Inc. stockholders’ equity |
|
126,942 |
|
|
|
97,321 |
|
Non-controlling interests |
|
63,776 |
|
|
|
- |
|
Total stockholders’ equity |
|
190,718 |
|
|
|
97,321 |
|
Total liabilities, redeemable non-controlling interests,
and stockholders’ equity |
$ |
296,619 |
|
|
$ |
217,703 |
|
|
|
|
|
|
|
|
|
ACM RESEARCH,
INC.Condensed Consolidated Statements of
Operations and Comprehensive Income
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
(Unaudited) |
|
(In thousands, except share and per share data) |
|
(In thousands, except share and per share data) |
Revenue |
$ |
47,665 |
|
|
$ |
33,427 |
|
|
$ |
111,062 |
|
|
$ |
82,916 |
|
Cost of revenue |
|
27,324 |
|
|
|
17,173 |
|
|
|
61,137 |
|
|
|
44,705 |
|
Gross profit |
|
20,341 |
|
|
|
16,254 |
|
|
|
49,925 |
|
|
|
38,211 |
|
Operating expenses: |
|
|
|
|
|
|
|
Sales and marketing |
|
3,924 |
|
|
|
3,886 |
|
|
|
11,524 |
|
|
|
8,679 |
|
Research and development |
|
4,343 |
|
|
|
3,492 |
|
|
|
13,241 |
|
|
|
9,598 |
|
General and administrative |
|
4,568 |
|
|
|
1,846 |
|
|
|
9,100 |
|
|
|
5,992 |
|
Total operating expenses, net |
|
12,835 |
|
|
|
9,224 |
|
|
|
33,865 |
|
|
|
24,269 |
|
Income from operations |
|
7,506 |
|
|
|
7,030 |
|
|
|
16,060 |
|
|
|
13,942 |
|
Interest income |
|
179 |
|
|
|
95 |
|
|
|
834 |
|
|
|
128 |
|
Interest expense |
|
(272 |
) |
|
|
(205 |
) |
|
|
(611 |
) |
|
|
(538 |
) |
Change in fair value of financial liability |
|
(6,533 |
) |
|
|
- |
|
|
|
(11,964 |
) |
|
|
- |
|
Unrealized gain on trading securities |
|
8,970 |
|
|
|
- |
|
|
|
8,970 |
|
|
|
- |
|
Other income (expense), net |
|
(1,759 |
) |
|
|
1,850 |
|
|
|
(933 |
) |
|
|
2,132 |
|
Equity income (loss) in net income (loss)
of affiliates |
|
182 |
|
|
|
(9 |
) |
|
|
539 |
|
|
|
260 |
|
Income before income taxes |
|
8,273 |
|
|
|
8,761 |
|
|
|
12,895 |
|
|
|
15,924 |
|
Income tax benefit (expense) |
|
1,747 |
|
|
|
328 |
|
|
|
(416 |
) |
|
|
(667 |
) |
Net income |
|
10,020 |
|
|
|
9,089 |
|
|
|
12,479 |
|
|
|
15,257 |
|
Less: Net income attributable to non-controlling interests and
redeemable non-controlling interests |
|
1,393 |
|
|
|
307 |
|
|
|
2,228 |
|
|
|
307 |
|
Net income attributable to ACM Research, Inc. |
$ |
8,627 |
|
|
$ |
8,782 |
|
|
$ |
10,251 |
|
|
$ |
14,950 |
|
Comprehensive income: |
|
|
|
|
|
|
|
Net income |
|
10,020 |
|
|
|
9,089 |
|
|
|
12,479 |
|
|
|
15,257 |
|
Foreign currency translation adjustment |
|
5,757 |
|
|
|
(2,591 |
) |
|
|
4,099 |
|
|
|
(2,902 |
) |
Total comprehensive income |
|
15,777 |
|
|
|
6,498 |
|
|
|
16,578 |
|
|
|
12,355 |
|
Less: Comprehensive income attributable to non-controlling
interests and redeemable non-controlling interests |
|
2,698 |
|
|
|
307 |
|
|
|
3,614 |
|
|
|
307 |
|
Total comprehensive income
attributable to ACM Research, Inc. |
$ |
13,079 |
|
|
$ |
6,191 |
|
|
$ |
12,964 |
|
|
$ |
12,048 |
|
|
|
|
|
|
|
|
|
Net income attributable to ACM Research, Inc.
per common share : |
|
|
|
|
|
|
|
Basic |
$ |
0.47 |
|
|
$ |
0.52 |
|
|
$ |
0.57 |
|
|
$ |
0.91 |
|
Diluted |
$ |
0.40 |
|
|
$ |
0.45 |
|
|
$ |
0.48 |
|
|
$ |
0.80 |
|
|
|
|
|
|
|
|
|
Weighted
average common shares outstanding used in computing per share amounts: |
|
|
|
|
|
|
Basic |
|
18,201,943 |
|
|
|
16,999,746 |
|
|
|
18,124,665 |
|
|
|
16,381,944 |
|
Diluted |
|
21,555,296 |
|
|
|
19,354,214 |
|
|
|
21,257,661 |
|
|
|
18,699,010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACM RESEARCH,
INC.Reconciliation of GAAP to Non-GAAP Financial
Measures
As described under “Use of Non-GAAP Financial Measures” above,
ACM presents non-GAAP gross margin, operating expenses, operating
income and net income attributable to ACM Research, Inc. as
supplemental measures to GAAP financial measures, each of which
excludes stock-based compensation (“SBC”) from the equivalent GAAP
financial line items. In addition, non-GAAP net income (loss)
attributable to ACM Research, Inc. excludes non-cash changes in
fair value of financial assets and liabilities The following table
reconciles gross margin, operating expenses, operating income and
net income attributable to ACM Research, Inc. to the related
non-GAAP financial measures:
|
Three Months Ended September 30, |
|
2020 |
2019 |
|
Actual(GAAP) |
SBC |
Other non-operatingadjustments |
Adjusted(Non-GAAP) |
Actual(GAAP) |
SBC |
Adjusted(Non-GAAP) |
|
(In thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
$ |
47,665 |
|
$ |
- |
|
$ |
- |
|
$ |
47,665 |
|
$ |
33,427 |
|
$ |
- |
|
$ |
33,427 |
|
Cost of revenue |
|
(27,324 |
) |
|
(44 |
) |
|
- |
|
|
(27,280 |
) |
|
(17,173 |
) |
|
(154 |
) |
|
(17,019 |
) |
Gross profit |
|
20,341 |
|
|
(44 |
) |
|
- |
|
|
20,385 |
|
|
16,254 |
|
|
(154 |
) |
|
16,408 |
|
Operating expenses: |
|
|
|
|
|
|
|
Sales and marketing |
|
(3,924 |
) |
|
(237 |
) |
|
- |
|
|
(3,687 |
) |
|
(3,886 |
) |
|
(172 |
) |
|
(3,714 |
) |
Research and development |
|
(4,343 |
) |
|
(193 |
) |
|
- |
|
|
(4,150 |
) |
|
(3,492 |
) |
|
(759 |
) |
|
(2,733 |
) |
General and administrative |
|
(4,568 |
) |
|
(2,305 |
) |
|
- |
|
|
(2,263 |
) |
|
(1,846 |
) |
|
(472 |
) |
|
(1,374 |
) |
Income from operations |
$ |
7,506 |
|
$ |
(2,779 |
) |
$ |
- |
|
$ |
10,285 |
|
$ |
7,030 |
|
$ |
(1,557 |
) |
$ |
8,587 |
|
Change in fair value of financial liability |
|
(6,533 |
) |
|
- |
|
|
(6,533 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
Unrealized
gain on trading securities |
|
8,970 |
|
|
- |
|
|
8,970 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
Net income
(loss) attributable to ACM Research, Inc. |
$ |
8,627 |
|
$ |
(2,779 |
) |
$ |
2,437 |
|
$ |
8,969 |
|
$ |
8,782 |
|
$ |
(1,557 |
) |
$ |
10,339 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
2020 |
2019 |
|
Actual(GAAP) |
SBC |
Other non-operatingadjustments |
Adjusted(Non-GAAP) |
Actual(GAAP) |
SBC |
Adjusted(Non-GAAP) |
|
(In thousands) |
|
|
|
|
|
|
|
|
Revenue |
$ |
111,062 |
|
$ |
- |
|
$ |
- |
|
$ |
111,062 |
|
$ |
82,916 |
|
$ |
- |
|
$ |
82,916 |
|
Cost of revenue |
|
(61,137 |
) |
|
(132 |
) |
|
- |
|
|
(61,005 |
) |
|
(44,705 |
) |
|
(213 |
) |
|
(44,492 |
) |
Gross profit |
|
49,925 |
|
|
(132 |
) |
|
- |
|
|
50,057 |
|
|
38,211 |
|
|
(213 |
) |
|
38,424 |
|
Operating expenses: |
|
|
|
|
|
|
|
Sales and marketing |
|
(11,524 |
) |
|
(495 |
) |
|
- |
|
|
(11,029 |
) |
|
(8,679 |
) |
|
(252 |
) |
|
(8,427 |
) |
Research and development |
|
(13,241 |
) |
|
(568 |
) |
|
- |
|
|
(12,673 |
) |
|
(9,598 |
) |
|
(939 |
) |
|
(8,659 |
) |
General and administrative |
|
(9,100 |
) |
|
(3,128 |
) |
|
- |
|
|
(5,972 |
) |
|
(5,992 |
) |
|
(1,515 |
) |
|
(4,477 |
) |
Income from operations |
$ |
16,060 |
|
$ |
(4,323 |
) |
$ |
- |
|
$ |
20,383 |
|
$ |
13,942 |
|
$ |
(2,919 |
) |
$ |
16,861 |
|
Change in fair value of financial liability |
|
(11,964 |
) |
|
- |
|
|
(11,964 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
Unrealized gain on trading securities |
|
8,970 |
|
|
- |
|
|
8,970 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
Net income
attributable to ACM Research, Inc. |
$ |
10,251 |
|
$ |
(4,323 |
) |
$ |
(2,994 |
) |
$ |
17,568 |
|
$ |
14,950 |
|
$ |
(2,919 |
) |
$ |
17,869 |
|
|
|
|
|
|
|
|
|
ACM Research (NASDAQ:ACMR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ACM Research (NASDAQ:ACMR)
Historical Stock Chart
From Apr 2023 to Apr 2024